Physician profile
Cornell Peters
NPI 1861487225
$7,312.72
in general payments reported to CMS, 2019-2025
53 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $621 · 2021: $904 · 2022: $1,011 · 2023: $1,004 · 2024: $1,491 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,013.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $802.51 | 2020-2025 | |
| Novo Nordisk INC | $792.82 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $575.48 | 2019-2025 | Breztri, Airsupra, Pulmicort |
| Indivior INC. | $534.11 | 2019-2024 | Sublocade |
| Lilly USA, LLC | $462.49 | 2020-2025 | Mounjaro, Emgality, Reyvow |
| Abbott Laboratories | $433.90 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Boston Scientific Corporation | $374.73 | 2024-2025 | Ams 700, Wavewriter Alpha Prime 16 |
| Pfizer INC. | $362.85 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $265.77 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.35 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $220.51 | 2022-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $203.19 | 2024-2025 | Belbuca, Xtampza |
| Kowa Pharmaceuticals America, INC. | $190.91 | 2022-2023 | Seglentis, Livalo |
| Ironwood Pharmaceuticals, INC | $138.49 | 2019-2023 | Linzess |
| Astellas Pharma US INC | $131.01 | 2023-2025 | Veozah |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cornell Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.